Abstract
Before considering effects of lipid-lowering drugs it may be useful to summarize the essentials in the pathogenesis of hyperlipoproteinemia in subjects with NIDDM. According to the work of Reaven and his group, an increase in VLDL secretion occurs with decreasing insulin response, the second fact is that actual serum levels of triglycerides (TG) are higly determined by VLDL secretion. The increase in VLDL production seems to depend mainly from a high turnover of free fatty acids [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Reaven GM (1990) Pathogepesis of Abnormal Very-Low-Density and High-Density Lipoprotein Metabolism in Patients with Non-Insulin-Dependent Diabetes Mellitus. In: Belfiore F, Molinatti GM, Reaven GM (eds) Tissue-Specific Metabolic Alterations in Diabetes. Front Diabetes, 10:134 –144
Kissebah AH, Alfarsi S, Evans DJ, Adams PW (1982) Integrated regulation of very-low-density lipoprotein triglyceride and apolipoprotein B kinetics in non-insulin-dependent diabete mellitus. Diabetes 31: 217–225
Kennedy L, Walshe K, Hadden DR, Weaver JA, Buchanan KD (1982) The effect of intensity dietary therapy on serum high-density lipoprotein cholesterol in patients with type II (non-insulin-dependent) diabetes mellitus: A prospective study. Diabetologia 23: 24–27
Bar-On H, Landau D, Berry E (1977) Serum high-density lipoprotein and univesity group diabetes program results. Lancet 1: 761
Hughes TA, Clements RS, Fairclough PK, Bell DSH, Segrest JP (987) Effect of insulin therapy on lipoproteins in non-insulin-dependent diabetes mellitus (NIDDM) Atherosclerosis 67: 105–114
Taskinen MR, Kuusi T, Helve E, Nikkila EA, Yki-Järvinen H (1988) Insulin therapy induces antiatherogenic changes of serum lipoproteins in non-insulin-dependent diabetes. Arterosclerosis 8: 168–177
Sirtori CR, Tremoli E, Sirtori M, Conti F, Paoletti R (1977) Treatment of hyer- triglyceridemia with metformin. Atherosclerosis 26: 583–592
Kesaniemi YA, Witztum JL, Steinbrecher UP (1983) Receptor-mediated cataboism of low density lipoprotein in man. Quantitation using glycosylated low density lipoprotein. J Clin Invest 71: 950–959
Nozaki S,. Vega GL, Haddox RJ, Dolan ET, Grundy SM (1990) Influence of lovastatin on concentrations and composition of lipoprotein subfractions. Atherosclerosis 84: 101–110
Grundy SM, Vega GL (1985) Influence of mevinoliri on metabolism of low density lipoproteins in primary moderate hypercholesterolemia. J Lip Res 26: 1464–1475
Vega GL, Krauss RM, Grundy SM (1990) Pravastatin therapy in primary moderate hypercholesterolemia; changes in metabolism of apolipoprotein B-containing lipoprotiens. J Int Med 227: 81–94
Ginsberg HN, Le N-A, Short MP, Ramakrishnan R, Desnick RJ (1987) Suppression of apolipoprotein B production during treatment of cholesterol ester storage disease with lovastatin: implication for regulation of apolipoprotein B. J Clin Invest 80: 1692–1698
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Schneider, J. (1993). Lipoproteins in Patients with NIDDM: Effects of Different Therapeutic Approaches. In: Steinmetz, A., Schneider, J., Kaffarnik, H. (eds) Hormones in Lipoprotein Metabolism. Recent Developments in Lipid and Lipoprotein Research. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-84855-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-84855-1_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-55995-5
Online ISBN: 978-3-642-84855-1
eBook Packages: Springer Book Archive